Study of Endometrial Immune and Microbiological Modifications in Cases of Recurrent Implantation Failure and/or Recurrent Pregnancy Loss

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-35
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

The IMERR study aims to improve understanding of certain causes of infertility related to recurrent implantation failure (RIF) and/or recurrent pregnancy loss (RPL), conditions that affect many women undergoing assisted reproductive technology (ART). Despite medical advances, some patients repeatedly fail to achieve pregnancy, or experience repeated miscarriages. These situations may be linked to subtle immune or microbial disturbances in the uterus. This study seeks to identify immune and microbiological profiles in the endometrium during the implantation window-a crucial period when the embryo attaches to the uterine wall. We will compare women who have experienced RIF and/or RPL with women who have had no such history. Blood and uterine samples will be analyzed to investigate whether certain immune or microbial features are associated with these reproductive failures. The ultimate goal is to uncover predictive factors that may explain why some women experience implantation failure or pregnancy loss, and to lay the foundation for future personalized treatments to improve reproductive outcomes.

Eligibility criteria

Qualifiers

Female aged ≥18 and <36 years

Undergoing assisted reproductive technology (ART) in a fertility center

Covered by the French national health insurance system

Study group: history of recurrent implantation failure (RIF) and/or recurrent pregnancy loss (RPL)

Disqualifiers

Pregnant at inclusion

Refusal to provide written informed consent

Antibiotic use within one month prior to endometrial biopsy Positive serology for hepatitis B, hepatitis C or HIV

Uterine anatomical abnormalities (e.g., polyps, cavity-distorting fibroids, untreated hydrosalpinx)

Trial design

Treatments tested in this trial

  • Endometrial Biopsy
  • Vaginal Swab
  • Blood sample
  • Pelvic ultrasound (±pelvic MRI)

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Collaborator

ADREGOF

Collaborator

URC-CIC Paris Descartes Necker Cochin

Collaborator